Shanghai RAAS Blood Products Co., Ltd. (002252)
Market Closed
25 Apr, 06:57
XSHE XSHE Primary ¥
6. 72
0
0%
¥
44.61B Market Cap
26.52 P/E Ratio
0.15% Div Yield
31,735,338 Volume
0.36 Eps
¥ 6.72
Previous Close Day Range
6.69 6.74
Year Range
6.42 8.68
Summary
002252 closed Friday higher at ¥6.72, an increase of 0% from Thursday's close, completing a monthly decrease of -2.04% or ¥0.14. Over the past 12 months, 002252 stock lost -6.93%.
002252 is not paying dividends to its shareholders.
The last earnings report, released on Oct 28, 2024, missed the consensus estimates by -0.01%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on XSHE (CNY).
Want to track 002252 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
002252 Chart
Shanghai RAAS Blood Products Co., Ltd. (002252) FAQ
What is the stock price today?
The current price is ¥6.72.
On which exchange is it traded?
Shanghai RAAS Blood Products Co., Ltd. is listed on XSHE.
What is its stock symbol?
The ticker symbol is 002252.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 44.61B.
Has Shanghai RAAS Blood Products Co., Ltd. ever had a stock split?
No, there has never been a stock split.
Shanghai RAAS Blood Products Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Jun Xu CEO | XSHE Exchange | CNE100000C31 ISIN |
| China Country | 3,350 Employees | - Last Dividend | 28 Sep 2016 Last Split | 23 Jun 2008 IPO Date |
Overview
Shanghai RAAS Blood Products Co., Ltd. is a prominent company based in Shanghai, China, specializing in the development, manufacturing, and sale of various blood products. Established in 1988, the company has grown to become one of China's leading suppliers in the blood product industry. Through its extensive research and development efforts, Shanghai RAAS has been able to offer a wide range of critical blood-derived products that are essential in the medical treatment of various diseases and conditions.
Products and Services
Shanghai RAAS Blood Products Co., Ltd. provides an expansive portfolio of blood products, catering to different medical needs. These include:
- Human Serum Albumin: Utilized commonly in the treatment of shock, burns, and other conditions requiring plasma volume replacement.
- Human Intravenous Immunoglobulin: Offers vital immune support for individuals with immune deficiencies and is used in the treatment of various autoimmune and inflammatory diseases.
- Human Coagulation Factor VIII: Essential for the management and treatment of hemophilia A, a genetic disorder impairing blood coagulation.
- Human Prothrombin Complex: Used in the management of bleeding disorders, especially for patients with deficiencies in clotting factors.
- Human Fibrinogen: A critical factor in blood clot formation, used in the treatment of congenital and acquired fibrinogen deficiency.
- Human Thrombin and Human Fibrin Adhesive: These products are used in surgeries as hemostatic agents to control bleeding.
- Human Immunoglobulin: Plays a role in boosting the immune system, especially for patients with weakened immune systems.
- Hepatitis B Immunoglobulin: Provides passive immunity to hepatitis B, used particularly after exposure to the virus or for newborns of infected mothers.
- Tetanus Immunoglobulin: Offers passive immunization against tetanus in cases of wounds likely to be contaminated with Clostridium tetani.
- Rabies Immunoglobulin: Provides immediate protection against the rabies virus following exposure before the vaccine starts to take effect.
Contact Information
Address: No. 2009, Wangyuan Road
Phone: 86 21 2213 0888
Website: https://www.raas-corp.com
2025 © Marketlog. All Rights Reserved.
